Beijing Tiantan Biological Products Co., Ltd. (600161.SS) reported a profit for full year that Dropped, from last year
The company's bottom line came in at RMB1.090 billion, or RMB0.55 per share. This compares with RMB1.549 billion, or RMB0.78 per share, last year.
The company's revenue for the period rose 2.3% to RMB6.168 billion from RMB6.031 billion last year.
Beijing Tiantan Biological Products Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB1.090 Bln. vs. RMB1.549 Bln. last year.-EPS: RMB0.55 vs. RMB0.78 last year.-Revenue: RMB6.168 Bln vs. RMB6.031 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.